Skip Navigation

Adalvo and Hikma Sign Exclusive Licensing Agreement to Commercialise a product in the Allergic Rhinitis space across MENA Markets

25 August 2022

Adalvo is pleased to announce that we have signed an exclusive licensing agreement with Hikma Pharmaceuticals PLC (Hikma), a multinational pharmaceutical company, to commercialise a nasal spray indicated in the treatment of Allergic Rhinitis (AR).  one of the main respiratory diseases with increasing prevalence.

The new exclusive licensing and supply deal with Hikma expands Adalvo’s respiratory endeavours in MENA. The licensed product is a combination treatment in a single advanced delivery system that has proven efficacy and safety in treating patients with AR. This medication will help more patients control their respiratory disease symptoms, with an advantage of a faster onset of action and fewer adverse effects.

Anil Okay, CEO at Adalvo comments: “We are thrilled to be partnering with Hikma, a well-established multinational Company having a track record of creating high-quality medicines and making them accessible to the people who need them. This collaboration further accelerates our growth at an international level, and underlines our capabilities of bringing differentiated, high value products to the market, whilst also expanding our allergy and respiratory pipeline.”

“This latest agreement with Adalvo aligns with our strategy of creating a well-diversified pipeline of high-value products, while further solidifying our commercial presence in MENA. By partnering with a dynamic and progressive company like Adalvo, we are building on our ongoing commitment to offering patients access to high-quality respiratory medications that actively support their treatment journey towards better health.” said Mazen Darwazah, Hikma’s Executive Vice Chairman and President of MENA.

About Adalvo

Adalvo is a global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, with commercial partnerships in more than 100 countries and for over 110 commercial partners globally. The company’s declared purpose is to make a difference for patients all over the world, driven by our smart collaboration network and commitment to delivering highest quality differentiated products and services to our partners.


With headquarters in Malta, the company has additional offices in more than 16 countries. At Adalvo, we know that our partners like to be bigger, better, and smarter in the dynamic pharmaceutical sector. That’s why our approach is unique, customized to our partners, and is designed to challenge the status quo: together, this helps our partners achieve their business goals.


We take pride in our ability to help its partners reach their goals – be those increasing revenues or pushing into new markets. While partners are a high priority, Adalvo is also committed to its purpose and mission to accelerate the growth and development of employees and local communities. Adalvo tirelessly strives for excellence in all of its endeavors, driven by a deep-rooted passion to making a difference for partners.


The company’s purpose driven culture is committed to improving the lives of patients around the world. Our dynamic leadership team brings significant experience and industry know-how to Adalvo, which has helped to establish the company as a reliable global partner.


About Hikma


Hikma helps put better health within reach every day for millions of people around the world. For more than 40 years, we’ve been creating high-quality medicines and making them accessible to the people who need them.

Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people’s lives.


We’re committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,700 colleagues are helping to shape a healthier world that enriches all our communities.


We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world.


For more information, please visit: